Cascadian Therapeutics (ONTY) 10-Q 2017 Q2 Quarterly report

Cascadian Therapeutics, Inc. 10-Q

EXHIBIT 32.2

CERTIFICATION PURSUANT TO 

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002 

(18 U.S.C. SECTION 1350)

I, Julia M. Eastland, certify, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that the Quarterly Report on Form 10-Q of Cascadian Therapeutics, Inc. for the quarterly period ended June 30, 2017, fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that information contained in such Quarterly Report on Form 10-Q fairly presents, in all material respects, the financial condition and results of operations of Cascadian Therapeutics, Inc. 

August 8, 2017	/s/ Julia M. Eastland
	Julia M. Eastland
	Chief Financial Officer, Chief Business Officer and Secretary
	(Principal Financial and Accounting Officer)

46